More about

Cardiomyopathy

News
January 26, 2024
4 min read
Save

After sudden cardiac death, genetic testing may provide answers, identify risks for family

After sudden cardiac death, genetic testing may provide answers, identify risks for family

Sudden death from cardiac causes is among the leading causes of death in the United States, yet predicting who might be at high risk remains a difficult task.

News
January 20, 2024
2 min read
Save

Pre-sports participation CV screening most accurate in children aged 12 years or older

Pre-sports participation CV screening most accurate in children aged 12 years or older

When children aged 8 to 15 years were screened for risk for before participating in sports, the diagnostic yield for identifying those at risk was higher in those aged 12 years or older, researchers reported.

News
January 11, 2024
3 min read
Save

‘Across the board’ benefits seen with acoramidis for transthyretin amyloid cardiomyopathy

‘Across the board’ benefits seen with acoramidis for transthyretin amyloid cardiomyopathy

Acoramidis, an investigational treatment for symptomatic transthyretin amyloid cardiomyopathy, was associated with marked improvements in all-cause mortality and CV-related hospitalizations compared with placebo, data show.

News
November 13, 2023
3 min read
Save

Screening for peripartum cardiomyopathy using AI-enhanced digital stethoscope shows promise

Screening for peripartum cardiomyopathy using AI-enhanced digital stethoscope shows promise

PHILADELPHIA — In the SPEC-AI trial, use of an artificial intelligence-enhanced digital stethoscope doubled the number of cases of peripartum cardiomyopathy identified among pregnant and postpartum women.

News
November 13, 2023
3 min read
Save

Regular marijuana use linked to risk for HF, major adverse heart, brain events

Regular marijuana use linked to risk for HF, major adverse heart, brain events

PHILADELPHIA — Two observational studies presented at the American Heart Association Scientific Sessions linked regular marijuana use to elevated risk for HF and elevated risk for major adverse cardiac and cerebrovascular events.

News
October 13, 2023
2 min read
Save

Despite panel support, FDA rejects patisiran for ATTR amyloidosis with cardiomyopathy

Despite panel support, FDA rejects patisiran for ATTR amyloidosis with cardiomyopathy

The FDA rejected a supplemental new drug application for patisiran to treat cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness.

News
October 13, 2023
4 min read
Save

‘One giant leap for HCM’: Gene therapy may reverse hypertrophic cardiomyopathy

‘One giant leap for HCM’: Gene therapy may reverse hypertrophic cardiomyopathy

Despite advances made for the treatment and management of hypertrophic cardiomyopathy, the condition remains a debilitating one for many patients, who are often undiagnosed until the disease has progressed.

News
September 13, 2023
5 min read
Save

FDA panel supports patisiran for ATTR amyloidosis with cardiomyopathy

FDA panel supports patisiran for ATTR amyloidosis with cardiomyopathy

An FDA panel voted 9-3 in favor of expanding approval of patisiran to patients with cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, noting modest benefits but no significant safety concerns.

News
August 09, 2023
3 min read
Save

Novel blood analysis suggests inflammation ‘plays a role’ in peripartum cardiomyopathy

Novel blood analysis suggests inflammation ‘plays a role’ in peripartum cardiomyopathy

New serum proteomic analyses suggest that a distinct dysregulation of inflammatory and cholesterol-related pathways drive peripartum cardiomyopathy, a rare but serious complication of pregnancy occurring more frequently among Black women.

News
July 18, 2023
2 min read
Save

In nonischemic cardiomyopathy requiring ICD, Black patients may have worse outcomes

In nonischemic cardiomyopathy requiring ICD, Black patients may have worse outcomes

In patients with an implantable cardioverter defibrillator for primary prevention, among those with nonischemic cardiomyopathy, Black patients were more likely to have arrhythmias, to receive ICD therapies and to die than white patients.

View more